| pubmed-article:11566623 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:11566623 | lifeskim:mentions | umls-concept:C0019699 | lld:lifeskim |
| pubmed-article:11566623 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:11566623 | lifeskim:mentions | umls-concept:C0007634 | lld:lifeskim |
| pubmed-article:11566623 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:11566623 | lifeskim:mentions | umls-concept:C0021756 | lld:lifeskim |
| pubmed-article:11566623 | lifeskim:mentions | umls-concept:C0007589 | lld:lifeskim |
| pubmed-article:11566623 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:11566623 | lifeskim:mentions | umls-concept:C0205160 | lld:lifeskim |
| pubmed-article:11566623 | lifeskim:mentions | umls-concept:C1446409 | lld:lifeskim |
| pubmed-article:11566623 | lifeskim:mentions | umls-concept:C1332714 | lld:lifeskim |
| pubmed-article:11566623 | lifeskim:mentions | umls-concept:C1334114 | lld:lifeskim |
| pubmed-article:11566623 | lifeskim:mentions | umls-concept:C1511938 | lld:lifeskim |
| pubmed-article:11566623 | lifeskim:mentions | umls-concept:C1514485 | lld:lifeskim |
| pubmed-article:11566623 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:11566623 | pubmed:dateCreated | 2001-9-21 | lld:pubmed |
| pubmed-article:11566623 | pubmed:abstractText | Interleukin-2 has been widely used in HIV-1+ subjects as an immunoactivating agent. In this study, we investigated cytokine production, Ki67 antigen expression and the modulation of the surface phenotype of the CD4/CD25+ subset as compared to the reciprocal CD4/CD25- subset in IL-2-treated HIV+ patients. Our findings suggest that CD4 T cells are heterogeneous in responding to IL-2, because CD4/CD25+ cells sharply increased their "memory" phenotype, their Ki67 antigen expression and were the main in vivo targets for IL-2-dependent proliferation during therapy, while the percentages of IFN-gamma+ (terminally differentiated) cells remained unchanged at the end of therapy. Conversely, the CD4+/CD25- subpopulation showed an expansion of differentiated cells and a slight increase in the proliferation rate. The use of anti-retroviral therapy alone (HAART) reduced the proliferation and increased the differentiation of both CD4 subsets. Our data suggest that IL-2 has a moderate capacity to activate resting T cells in vivo and is probably unable to boost HIV-1 from latency to the replicative state. | lld:pubmed |
| pubmed-article:11566623 | pubmed:language | eng | lld:pubmed |
| pubmed-article:11566623 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11566623 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:11566623 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11566623 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11566623 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11566623 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11566623 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11566623 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11566623 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11566623 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11566623 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:11566623 | pubmed:issn | 1148-5493 | lld:pubmed |
| pubmed-article:11566623 | pubmed:author | pubmed-author:D'AndreaMM | lld:pubmed |
| pubmed-article:11566623 | pubmed:author | pubmed-author:ZanussiSS | lld:pubmed |
| pubmed-article:11566623 | pubmed:author | pubmed-author:CaffauCC | lld:pubmed |
| pubmed-article:11566623 | pubmed:author | pubmed-author:CrepaldiCC | lld:pubmed |
| pubmed-article:11566623 | pubmed:author | pubmed-author:CaggiariLL | lld:pubmed |
| pubmed-article:11566623 | pubmed:author | pubmed-author:BortolinM TMT | lld:pubmed |
| pubmed-article:11566623 | pubmed:author | pubmed-author:PaoliP DPD | lld:pubmed |
| pubmed-article:11566623 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:11566623 | pubmed:volume | 12 | lld:pubmed |
| pubmed-article:11566623 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:11566623 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:11566623 | pubmed:pagination | 430-6 | lld:pubmed |
| pubmed-article:11566623 | pubmed:dateRevised | 2008-11-21 | lld:pubmed |
| pubmed-article:11566623 | pubmed:meshHeading | pubmed-meshheading:11566623... | lld:pubmed |
| pubmed-article:11566623 | pubmed:meshHeading | pubmed-meshheading:11566623... | lld:pubmed |
| pubmed-article:11566623 | pubmed:meshHeading | pubmed-meshheading:11566623... | lld:pubmed |
| pubmed-article:11566623 | pubmed:meshHeading | pubmed-meshheading:11566623... | lld:pubmed |
| pubmed-article:11566623 | pubmed:meshHeading | pubmed-meshheading:11566623... | lld:pubmed |
| pubmed-article:11566623 | pubmed:meshHeading | pubmed-meshheading:11566623... | lld:pubmed |
| pubmed-article:11566623 | pubmed:meshHeading | pubmed-meshheading:11566623... | lld:pubmed |
| pubmed-article:11566623 | pubmed:meshHeading | pubmed-meshheading:11566623... | lld:pubmed |
| pubmed-article:11566623 | pubmed:meshHeading | pubmed-meshheading:11566623... | lld:pubmed |
| pubmed-article:11566623 | pubmed:meshHeading | pubmed-meshheading:11566623... | lld:pubmed |
| pubmed-article:11566623 | pubmed:meshHeading | pubmed-meshheading:11566623... | lld:pubmed |
| pubmed-article:11566623 | pubmed:meshHeading | pubmed-meshheading:11566623... | lld:pubmed |
| pubmed-article:11566623 | pubmed:meshHeading | pubmed-meshheading:11566623... | lld:pubmed |
| pubmed-article:11566623 | pubmed:meshHeading | pubmed-meshheading:11566623... | lld:pubmed |
| pubmed-article:11566623 | pubmed:meshHeading | pubmed-meshheading:11566623... | lld:pubmed |
| pubmed-article:11566623 | pubmed:articleTitle | Effects of interleukin-2 therapy on the proliferation and differentiation of CD4/CD25 positive and CD4/CD25 negative cells in HIV+ patients. | lld:pubmed |
| pubmed-article:11566623 | pubmed:affiliation | Microbiology, Immunology and Virology, Centro di Riferimento Oncologico, Aviano, Italy. | lld:pubmed |
| pubmed-article:11566623 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:11566623 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:11566623 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:11566623 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
